CHE CHEMED CORP
Price Chart
Executive Summary
Chemed Corp reported flat Q4 2025 revenue of $639.3 million but a 9% decline in GAAP EPS to $5.48. The VITAS segment showed modest growth in net patient revenue (1.9%) and admissions (6%), while Roto-Rooter revenue declined 3.7%. The company provided strong 2026 guidance with EPS expected to grow to $23.25-$24.25, driven by a significant reduction in Medicare Cap billing limitations and projected revenue growth across both segments.
Key Financial Metrics
Actionable Insight
The stock may react positively to the strong 2026 guidance despite weak current results, particularly the significant reduction in Medicare Cap headwinds. Monitor VITAS admissions growth and Roto-Rooter margin recovery as key indicators of execution. The company's share repurchase activity ($174.6M in the quarter) provides additional support.
Key Facts
- Q4 2025 revenue was $639.3 million, essentially flat YoY
- GAAP EPS was $5.48, down 9% YoY; Adjusted EPS was $6.42, down 6% YoY
- VITAS net patient revenue increased 1.9% to $418.8 million with 6% growth in admissions
- Roto-Rooter revenue decreased 3.7% to $220.6 million with significant margin compression
- 2026 guidance projects EPS of $23.25-$24.25 (up from $21.55 in 2025) with VITAS revenue growth of 5.5%-6.5% and Roto-Rooter growth of 3.0%-3.5%
- Medicare Cap billing limitations expected to decrease to $9.5 million in 2026 from $27.2 million in 2025
Financial Impact
Revenue flat at $639.3M, EPS down 9% to $5.48, but 2026 guidance shows significant improvement with EPS expected to grow to $23.25-$24.25
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| VITAS | $418.8M | +1.9% |
| Roto-Rooter | $220.6M | -3.7% |
Risk Factors
- Roto-Rooter segment showing declining revenue and significant margin pressure
- Execution risk on the optimistic 2026 guidance, particularly the margin improvement targets
- Concentration risk in VITAS segment's Medicare reimbursement policies
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000019584-26-000002 |
| Document: che-20260225x8k.htm | 0000019584-26-000002 |
| Document: 0000019584-26-000002-index-headers.html | 0000019584-26-000002 |
| Document: 0000019584-26-000002-index.html | 0000019584-26-000002 |
| Document: 0000019584-26-000002.txt | 0000019584-26-000002 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 18, 2026
22d ago
|
Press Release
| $441.62 $437.33 | ▼ −0.97% | ▼ −2.59% | $439.13 (−0.56%) |
|
May 1, 2026
5w ago
|
Insider Cluster
| $422.16 $424.26 | ▲ +0.50% | ▼ −1.85% | $439.13 (+4.02%) |
|
Apr 23, 2026
6w ago
|
8-K
| $421.11 $424.98 | ▲ +0.92% | ▲ +0.01% | $439.13 (+4.28%) |
|
Apr 23, 2026
6w ago
|
Press Release
| $421.11 $424.98 | ▲ +0.92% | ▲ +0.01% | $439.13 (+4.28%) |
|
Apr 13, 2026
8w ago
|
8-K
| $387.62 $385.77 | ▼ −0.48% | ▼ −3.77% | $439.13 (+13.29%) |
|
Feb 25, 2026
14w ago
|
8-K
| $396.63 $412.16 | ▲ +3.92% | ▲ +5.04% | $439.13 (+10.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access